
Adenosine Receptor Blockade with Ciforadenant ± Atezolizumab in Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)

Fong L¹, Chu M², George S³, Hughes B⁴, Carthon B⁵, Merchan J⁶, Harshman L⁷, Munneke B⁸, Kwei L⁸, Hotson A⁸, Mobasher M⁸, Miller R⁸

¹UCSF Comprehensive Cancer Center, San Francisco CA, ²Cross Cancer Institute, Buffalo NY, ⁴Royal Brisbane Hospital, Brisbane Australia, ⁵Winship Cancer Institute, Buffalo NY, ⁴Royal Brisbane Australia, ⁵Winship Cancer Institute, Buffalo NY, ⁴Winship Cancer Institute, ⁵Winship Cancer Institute, ⁵Winship Cancer Institute, ⁵Winship Cancer Institut

ADENOSINE INHIBITS ANTI-TUMOR IMMUNITY



PATIENT CHARACTERISTICS

Median Age (years)	68.0
Median Prior Treatments (range)	3.0 (1-6)
Androgen blockade	13/35 (37%)
Chemotherapy	1/35 (3%)
Androgen blockade and chemotherapy	21/35 (60%)
Metastasis Burden:	
Node only	13/35 (37%)
Visceral only	3/35 (9%)
Node and Bone	4/35 (11%)
Bone and/or node and visceral	15/35 (43%)
Prior Anti-PD-(L)1 Exposure	
Naive	33/35 (94%)
Resistant/refractory	1/35 (3%)
Missing	1/35 (3%)

TREATMENT EMERGENT ADVERSE EVENTS

Any Grade

10 (41.7)

3 (12.5)

3 (12.5)

2 (8.3)

5 (20.8)

2 (8.3)

2 (8.3)

3 (12.5)

2 (8.3)

2 (8.3)

2 (8.3)


Grade 3/4


1 (9.1)

Ciforadenant


(n=11)


ANTI-TUMOR ACTIVITY WITH CIFORADENANT ± ATEZOLIZUMAB






IMMUNE CORRELATES WITH Tx & RESPONSE






DURATION OF TREATMENT




Ciforadenant Ciforadenant + Atezolizumab Ongoing



CONCLUSIONS

- Ciforadenant ± atezolizumab treatment was well tolerated.
- Ciforadenant demonstrated anti-tumor activity in heavily pretreated mCRPC patients as monotherapy and in combination with atezolizumab.
- Confirmed DCR (established with ≥ 2 scans) = 20% + additional pts with unconfirmed SD continuing on treatment
- Tumor regression occurs in 11/35 pts, including 2 treated with monotherapy
- Expression of CD73, an ecto-enzyme that produces adenosine, correlates with expression of a recently described Adenosine Gene Signature, supporting the potential relevance of adenosine in prostate cancer.
- Cytokine changes after treatment consistent with an immune response.
- Patient followup continues. Updated results planned for 2020 ASCO Annual Meeting

PROTOCOL DESIGN SUMMARY



Measurable disease

Prior anti-PD-(L)1 allowed

Progressive disease on prior therapy

Failed up to 5 prior therapies No selection for PD-L1 expression

Treated until disease progression or toxicity

At least 5% of any grade in any treatment

Any Grade

3 (27.3)

3 (27.3)

1 (9.1)

Fatigue

Nausea

Anemia

Pruritus

Arthralgia

Back pain

Headache

Myalgia

Pyrexia